Halberd Corporation Archives - Page 4 of 4

Feb 16 2021

Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

By Admin|2021-02-15T21:23:39-05:00February 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens. The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally ...

Jan 14 2021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

By Admin|2021-01-13T18:47:16-05:00January 14th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms. This proprietary combination of nutritional supplements is based on numerous ...

Jan 12 2021

Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article

By Admin|2021-01-11T19:57:47-05:00January 12th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 12, 2021 – Halberd Corp. (OTC PINK: "HALB") was recently included alongside Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021. Halberd was noted to be working in a different direction from the vaccine producers. ...

Dec 23 2020

Halberd Corporation Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein

By Admin|2020-12-22T21:04:30-05:00December 23rd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 23, 2020 – Halberd Corp. (OTC PINK: "HALB") research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein. Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd’s initial antibody. Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only ...

Dec 17 2020

Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19

By Admin|2020-12-16T20:11:40-05:00December 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month. The procedure is ...

Dec 10 2020

Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast

By Admin|2020-12-09T21:39:40-05:00December 10th, 2020|Featured, Investor News, News|0 Comments

Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began ...

Dec 7 2020

Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing

By Admin|2020-12-06T16:39:08-05:00December 7th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research. The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein. Scientific details of the testing to date will ...

Dec 2 2020

Halberd Corporation’s Covid-19 Technology Recognized by Momentum Observer

By Admin|2020-12-01T19:46:42-05:00December 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ). The article featured Halberd's nasal spray currently under development that could be an effective alternative ...

Dec 1 2020

Halberd Corporation Advisory Board Reorganization Announced

By Admin|2020-11-30T19:45:04-05:00December 1st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 1, 2020 – Halberd Corp. (OTC PINK: "HALB") announces the reorganization of its Scientific Advisory Board. The new Advisory Board will consist of two sub-boards: a multi-disciplined Scientific Advisory Board focused on biomedical issues and a Business Advisory Board focusing on business issues. The two boards will interface on a regular ...

Nov 25 2020

Halberd Corp. CEO Interviewed on Money TV;
Discusses 2020 Accomplishments and Plans

By Admin|2020-11-24T20:59:01-05:00November 25th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV. Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman ...

Previous 34